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Summary
Latent TB infection (LTI)-asymptomatic nontransmissiv tuberculosis infection with hidden persistence of M.tubercu-
losis in host organism. The problem of detection of latent tuberculosis infection is very urgent and difficult task. 140 in-
dividuals suspected of tuberculosis were  examined using conventional  clinical  and laboratory methods of examination, 
setting skin immunological reactions to detected delayed hypersensitivity- tuberculin skin test  (TST) and Diaskintest 
(DST). All the patient underwent determination of total antibodies to M.tuberculosis by ELISA. According to the data of 
examination 97 individuals were found to have latent tuberculosis infection and 43-different forms of pulmonary tubercu-
losis.  Based on the results of the study it can be agued that: 1) The use of DST allows more accurately differentiate latent 
tuberculosis infection and its activation. 2) Detection of total antibodies to MBT in the range 0,14-2,28 UOD is typical 
for persons with latent tuberculosis infection.  3) Determination of anti-TB antibodies and their level by ELISA can serve 
as an additional criterion for the diagnosis of tuberculosis and determine the activity of tuberculosis infection.4) With the 
exception of the local form of tuberculosis, persons with positive DST, with the level of anti-TB antibodies in the range 
0,14-2,28 UOD and with the syndrome of General disorders should be considered as patients with a borderline condition 
who need preventive anti - tuberculosis chemotherapy.
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Резюме. Изучение возможности усовершенствовании дифференциации латентной и активной туберку-
лезной инфекции
Латентная туберкулезная инфекция (ЛТИ) –асимптоматичная нетрасмиссивная туберкулезная инфекция со 
скрытой персистенцией. M.tuberculosis в организме человека. Дифференциация ЛТИ и активного туберкулеза все 
еще остается  довольно сложно разрешаемой проблемой. 140 лиц с подозрением на туберкулез были комплексно 
обследованы с применением общепринятых клинико-лабораторных методов обследования, а так же проведения 
кожного туберкулинового теста (TST) и Диаскинтеста (DST). Качественного и количественного определения сум-
марных противотуберкулезных антител методом ИФА. По результатам обследования у 97 лиц была выявлена 
ЛТИ, у 43 - различные формы туберкулеза легких. Основываясь на результатах исследования можно утверждать 
что:   
1) Применение DST позволяет более точно дифференцировать ЛТИ и ее активизацию. 2) У лиц с ЛТИ выяв-
ляются суммарные ПТА в диапазоне 0,14-2,28 ед. ОП. 3) Определение уровня ПТА методом ИФА может служить 
дополнительным критерием активности туберкулезной инфекции. 4) При исключении  локальной формы  тубер-
кулеза, лица с положительным DST с уровнем ПТА в диапазоне 0, 14- 2,28 ед. ОП и синдромом общих нарушений 
должны рассматриваться, как пациенты с пограничным состоянием, которым необходимо проводить превентив-
ную  противотуберкулезную химиотерапию. 
Ключевые слова: латентная туберкулезная инфекция, кожный туберкулиновый тест, Диаскинтест,  противо-
туберкулезные антитела.
Introduction. In many contries, regardless of the 
level of economic development, the incidence  of tu-
berculosis is increasing, so that tuberculosis can be 
classified as a resurgent infection (1). 
Latent tuberculosis infection is a reservoir of fu-
ture tuberculosis, the problem of detection of latent 
tuberculosis infection is a very urgent and difficult 
task (2,3,4,5). 
Latent TB infection (LTI)-asimptomatic non-
transmissive tuberculosis infection with hidden per-
sistence of Mycobacteria in the host organism [2,6]. 
The phenomenon of persistence of bacteria caus-
es an increased interest around the world [2,3,4, 
5,7,8,9,10]. The problem of differentiation of latent 
and active TB is very important, but difficult and 
not yet completely solvable [6,11]. According to the 
World Health Organization (WHO), one third of all 
humanity has  LTI 5-20% of those infected there is 
a risk of development of active tuberculosis (TB) 
during their lifetime and in the majority of cases TB 
develops in 2-5 years of infection [8,12]. The gap 
between infection and the development of tubercu-
losis is unique for contagious disease [9,13].   Thus, 
the LTI is a tank of the future TB. Infection control 
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(measures to reduce the incidence, early diagnosis 
and treatment) is the most important strategy to com-
bat TB.  The decrease in the number of people infect-
ed with M.tuberculosis and preventing new cases of 
disease is achieved by preventive therapy of persons 
with LTI [10, 11, 12,14,15,16]. Therefore for infec-
tion control should be more clearly delineate a the 
range of persons with LTI in the need of preventive 
therapy. The main methods of determination LTI  are 
tuberculin tests revealing delayed type hypersensitiv-
ity.  It is believed that the only convincing evidence 
of the presence of MBT in the body before the devel-
opment of local changes is the reaction of  delayed 
hypersensitivity, determined by skin test using tuber-
culin (13,14,17,18).  For carrying out the reaction us-
ing PPD (purified protein derivative). However, the 
PPD contains more than 200 antigens derived from 
M. bovis and M.humanus, a part of these antigens 
locate in other non-tubercular mikobacteria. For this 
reason, a positive test can be registered not only in 
case of MBT infection, but also in, nontuberculous 
mycobacteria infection as well as a certain period af-
ter BCG vaccination [15,16,17,19,20,21].Decording 
of M. tuberculosis genome [18] permit to use separate 
specific MBT proteins for diagnosis of tuberculosis. 
In the genome of the MBT around 4000  proteins cod-
ed and genes profile expressed at different stages of 
infection can vary [19, 20, 21, 22, 23,24,25,26,27]. 
The two most widely used for diagnostic purposes 
antigens ESAT-6 (Early Secreted Antigenic Target 
6) and CFP-10 (Culture Filtrate Protein 10) encod-
ed in the zone of RD1 M. tuberculosis genome and, 
they express when reproduction of Mycobacteria and 
absent in m. bovis BCG and most non-tuberculo-
sis Mycobacteria. They are related to the virulence 
of M. tuberculosis [28,29,30,31,32]. These antigens 
have been used to create diaskintest (tuberculous 
recombinant allergen) that represents a complex of 
recombinant protein CFP-10 and ESAT-6 produced 
genetically modified culture of Escherichia Coli BL-
21 (DE3)/p CFP-ESAT and destined for intradermal 
test with the purpose of revealing delayed-type hy-
persensitivity [32,33,34,35]. The active stage of tu-
berculosis is characterized by intensive production 
of anti- TB antibodies, which can be detected by en-
zyme immunoassay in a month from the beginning 
the of activation of mycobacteria. The high specifici-
ty and sensitivity of the test is achieved by the use of 
specific antigens for M.tuberculosis, which excludes 
false positive results in vaccinated and infected with 
other bacteria.
The purpose of the study. The aim of the study is 
finding the  objective indicators (other than tuberculin 
test and history data)to identify LTI and to compare 
the diagnostic possibilities of tuberculin intradermal 
tests (TST) and allergen tuberculous recombinant-di-
askintest  (DST) to identify activation of LTI  and de-
termination of the titer of antibodies to MBT antigens 
in persons with latent tuberculosis infection and in 
patients with tuberculosis, their comparative analysis. 
Materials and methods.  We examined 140 
individuals suspected of tuberculosis of these, 
among 140 study were 81 males and 59 females 
aged from 2 to 17 years old, the average age of  8.7 
± 0.4 years old. All have carefully assembled his-
tories, clinical and x-ray examination, explored the 
peripheral blood (complete blood count) and sputum 
examination on the presence of AFB.    97 individu-
als suspected according to the clinical, radiological, 
laboratory data and results of skin immunological test 
reactions were to found to have latent tuberculosis in-
fection, and 43-different forms of pulmonary tubercu-
losis. Detection of cellular immune response carried 
out using diaskintest based on an evaluation of de-
layed-type hypersensitivity. We used the intradermal 
injection of diaskintest at a dose of 2mkg in 0.1 ml, 
containing ESAT6-CFP-10 (Lecco, Russia) present in 
virulent strains of Mycobacterium tuberculosis. The 
reaction was visually evaluated after 72 h and was 
measured the size of induration in millimetres. The 
result was considered negative in the absence of in-
filtration, doubtful if hyperemia without infiltration, 
positive if there is infiltration (papules) of any size, 
hyperergic-when the diameter of infiltration 15 mm 
and more, formation vesicle  and necrosis and (or) 
the presence of lymphangitis, lymphadenitis.      For 
the evaluation of delayed-type hypersensitivity also 
conducted intradermal tuberculin test (routine meth-
od).TST and DST was carried out in parallel at 100 
persons and at 40-only DST.
All the patients underwent qualitative and quan-
titative determination  of total antibodies to M.tuber-
culosis in serum by ELISA. Tuberculosis  antibodies 
were detected using  a set of “AT-Туб-Бест” on the 
enzyme immunoassay “Bioscreen-500” (USA).  
All the observed persons showed some signs of 
the syndrome of General disorders (intoxication), 
which was characterized by pale skin decreased tis-
sue turgor, periorbital cyanosis, body weight deficien-
cy, decreased appetite, General malaise. In individu-
als with positive DST (62- 44,3%)    they were more 
numerous and pronounced. 
Statistic calculating of data performed using com-
puter programs Microsoft Excel for Windows, Statis-
tica.  
Results and discussion.  During the research  of 
skin immune tests (TST and DST) carried out in par-
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allel it was found that 99.0 ± 1.0% of examined per-
sons may be considered infected. Only one TST reac-
tion  was doubtful (4 mm diameter papule formation). 
Hyperergic reaction to tuberculin intradermal injec-
tion has evolved from 19.0 ± 3.9% surveyed, papule 
with the formation of vesicles from 5.0 ± 2.2%.    At 
the same time, positive reaction to the DST was de-
tected only in 25.0 ± 1.0% of the surveyed hyperergic 
reaction in 16.0 ± 3.7%. İn  75.0 ± 4.3% surveyed 
reaction to DST was negative.
Table 1. 
Results of skin immune tests (TST and DST) carried 
out in parallel.
The severity of reaction TST n = 100 DST n = 100
Positive 99.0 ± 1.0% 25.0 ± 1.0%
Hyperergic 19.0 ± 3.9% 16.0 ± 3.7%
With the formation of 
vesicles 5.0 ± 2.2% 3.0 ± 1.7%
Doubtful 1.0 ± 1.0% 0.0%
Negative 0.0% 75.0 ± 4.3%
As a result, a comprehensive clinical-radiolog-
ical and laboratory study among surveyed revealed 
3 patients with tuberculosis. In 17 years old pa-
tients,TST-doubtful (papule with diameter of 4 mm) 
DST- hperergic reaction (papule with a diameter of 17 
mm), complaining of weakness, loss of appetite, pro-
ductive cough, radiographically changes were iden-
tified, allowing diagnosis “infiltrative tuberculosis in 
the phase of destruction”, in the sputum AFB+.In 14 
years old patient  DST positive with the formation 
of papule (diameter of 10 mm) and a negative TST 
tuberculouse mesenteric adenitis was identified. And 
finally, 16 years old patient, with  hyperergic DST(-
papule-18 mm with vezikule) and hyperergic TST (17 
mm papule) identified tuberculosis of cervical lymph 
nodes.    Significantly less positive reaction to the 
DST (25.0 ± 4.3%) than the TST (99.0 ± 1.0%) have 
surveyed possible because, as shown above, the DST 
identifies the intensification of latent TB infection as 
antigens presented in DST expressed when reproduc-
tion of Mycobacteria and associated with virulence of 
the MBT. Match results of TST and DST was deter-
mined largely by the hyperergic reactions (9 people). 
Interest results of TST (papule with a diameter of 4 
mm) and with a diameter of 14 mm papules formation 
on DST from patient with infiltrative pulmonary tu-
berculosis in the phase of destruction. Thus, we have 
got several contradictory data necessitate further in-
vestigation with a view to a comparative analysis of 
the effectiveness of two skin immunologic tests in 
detecting latent TB infection and its activation is nec-
essary.     
It was found that in persons without clinical and 
radiological signs of active tuberculosis, the level 
of antibodies determined by the optical density was 
greater than 0, 14 units (negative) and less than 2, 28 
units (positive), in the range from 0, 27 to 1, 36 units. 
In patients with tuberculosis, the level of optical den-
sity varied between 2,5 units (positive) and 2,83 units 
(positive). Thus, at the detection of latent tuberculosis 
infection, along with convention research methods, it 
is possible to use the detection of total antibodies to 
M.tuberculosis in the range of 0,14-2,28 UOD (units 
of optical density). Taking in account the above men-
tioned high specificity  and sensitivity of the test it 
can be assumed that this methods of examination can 
be successfully used in distinguishing the active and 
latent course of tuberculosis infection. The syndrome 
of General disorders revealed in the examined per-
sons, taking into account the level of antituberculosis 
antibodies, can be interpreted as a set of symptoms  of 
tuberculosis intoxication, with the consequents need 
for preventive measure, one of which is the appoint-
ment of preventive chemotherapy to these persons.    
Conclusion. So, detection of total antibodies to 
MBT in the range 0,14-2,28 UOD is typical for per-
sons with latent tuberculosis infection.
Determination of anti-TB antibodies and their 
level by ELISA can serve as an additional criterion 
for the diagnosis of tuberculosis and determine the 
activity of tuberculosis infection. 
The results of ELISA on the determination of an-
ti-TB antibodies can be used to confirm the tubercu-
losis etiology of the syndrome of General disorders. 
In all patients with tuberculosis the results of DST 
was positive, so diaskintest can be used as one of the 
indicators of latent tuberculosis infection and its ac-
tivation. 
With the exception of the local form of tubercu-
losis, persons with positive DST, with the level of an-
ti-TB antibodies in the range 0,14-2,28 UOD and the 
syndrome of General disorders should be considered 
as patients with a borderline condition who need pre-
ventive anti tuberculosis chemotherapy.
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